Revista Brasileira de Farmacognosia xxx (2017) xxx–xxx

Brazilian Journal of Pharmacognosy
REVISTA BRASILEIRA DE FARMACOGNOSIA
www.elsevier.com/locate/bjp

Short communication

Impact of chrysosplenetin, per se or in combination with artemisinin, on breast cancer resistance protein (Bcrp)/ABCG2 mRNA expression levels in mice small intestine

Wei Ma[a,1], Yuanyuan Zhang[a,1], Yanli Zhang[b,1], Chenxu Zhang[a], Jianhuan Wang[a], Liping Ma[a], Bei Yang[a], Xiuli Wu[a,c,d,*], Jing Chen[a,c,d,*]

[a] School of Pharmacy, Ningxia Medical University, Yinchuan, China
[b] Department of Pathogen Biology and Immunology, School of Basic Medial Science, Ningxia Medical University, Yinchuan, China
[c] Ningxia Engineering and Technology Research Center for Modernization of Hui Medicine, Yinchuan, China
[d] Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education (Ningxia Medical University), Yinchuan, China

ARTICLE INFO

Article history:
Received 22 February 2017
Accepted 14 June 2017
Available online xxx

Keywords:
Chrysosplenetin
Artemisinin
Bcrp/ABCG2 mRNA expression
Western blot
RT-qPCR

ABSTRACT

Our previous work revealed that chrysosplenetin in combination with artemisinin inhibited *in vivo* P-glycoprotein (P-gp, one of classic multi-drug resistance proteins) mediated digoxin transportation activity by reversing the upregulated P-gp/Mdr1 mRNA expression levels by artemisinin. Therefore, chrysosplenetin might be a potential artemisinin-resistance reversal agent as a P-gp inhibitor. But it still remains unknown if chrysosplenetin has an impact on another pivotal multi-drug resistance protein, breast cancer resistance protein (Bcrp), which is co-expressed with P-gp in apical membrane of intestinal epithelial cell and overlaps some of the substrates and inhibitors. This study, therefore, further addressed the impact of chrysosplenetin, per se or in combination with artemisin, on Bcrp/ABCG2 mRNA expression levels in mice small intestine determined by western blot and real time-quantitative polymerase chain reaction (RT-qPCR) assay. The drugs were intragastrically administrated once per day for 7 days. Novobiocin, a known Bcrp inhibitor, was observed to have no impact on Bcrp/ABCG2 levels with or without artemisinin versus vehicle. Interestingly, artemisinin alone attenuated Bcrp level while chrysosplenetin alone increased it ($p < 0.05$). Relative mRNA level was significantly decreased when co-used with artemisinin and chrysosplenetin in ratio of 1:2 ($p < 0.05$). The discrepant results for chrysosplenetin on Bcrp/ABCG2 mRNA expressions might be closely related to the transcriptional or posttranscriptional regulation.

Introduction

The human ATP-binding cassette (ABC) proteins belong to a large protein superfamily; thus far, 48 ABC transporters have been identified in humans and twelve of them have been recognized as putative drug transporters. Among them, P-glycoprotein (P-gp, gene symbol ABCB1 or Mdr1), the multidrug resistance protein 1 (MRP1, gene symbol ABCC1), and the breast cancer resistance protein (BCRP, gene symbol ABCG2) are the best distinguished and most paramount drug transporters of multi drug resistance (MDR) (Gillet and Gottesman, 2011). There is mounting evidence to support that human BCRP/rat Bcrp plays a pivotal role in drug disposition by expelling a broad range of structurally different metabolites out of cells. Bcrp substantially overlaps with substrates and inhibitors of P-gp or MRP1 and resembles P-gp in tissue distribution and expression. In this regard, a very active Bcrp transporter could probably diminish drug delivery to the target organs which leads to MDR, despite peripheral drug concentrations being within their therapeutic extent.

Bcrp is composed of 655 amino acids (72 kDa) and organized into six transmembrane α-helices, containing only one nucleotide-binding domain (NBD) near its *N*-terminal and one membrane-spanning domain (MSD) (Lecerf-Schmidt et al., 2013; Noguchi et al., 2014; Mao and Unadkat, 2015). Therefore, Bcrp per se is a half transporter that transforms to a functional efflux pump when a disulfide bridge at Cys 603 of two proteins is

* Corresponding authors.
E-mails: xiuli2005@163.com (X. Wu), chenjing@nxmu.edu.cn (J. Chen).
[1] These authors contributed equally to this work.

https://doi.org/10.1016/j.bjp.2017.06.005

homodimerized (Lecerf-Schmidt et al., 2013; Noguchi et al., 2014; Mao and Unadkat, 2015) and confers an atypical MDR phenotype (Lagas et al., 2009; Ni et al., 2010).

To date, artemisinin antimalarial drugs are still of the utmost importance in the worldwide combination therapy of resistant falciparum malaria (Tripathi et al., 2013). Artemisinin resistance, defined as a delayed clearance of parasites after clinical therapy, has been reported (Meshnick et al., 1996; White, 2004). The mechanism of artemisinin resistance remains unclear and probably dominated by multiple mechanisms, which involved numerous multidrug resistance proteins such as several members of the ABC transporter super-family (Alcantara et al., 2013). This causes a low bioavailability and blood concentration for terminal drugs (Meng et al., 2014).

Numerous polymethoxylated flavonoids are discovered to modulate the activity of drug metabolizing enzymes and ABC transporters, which raises the potential for alterations in the pharmacokinetics of substrate drugs (Wesolowska, 2011; Yuan et al., 2012). Chrysosplenetin is one of the known polymethoxylated flavonoids in *Artemisia annua* L. and other several Chinese herbs (Numonov et al., 2015). In our previous work, chrysosplenetin was observed to improve the bioavailability and anti-malarial efficiency of artemisinin in combination ratio of 1:2 partially relying on its strong inhibition on rat CYP3A metabolic activity in an un-competitive manner (Wei et al., 2015) and on P-gp *in vivo* efflux efficacy (Yang et al., 2016) via reversing the up-regulated P-gp/Mdr1 mRNA expression levels by artemisinin (Ma et al., 2017). Hence, chrysosplenetin might be a dual inhibitor on CYP3A and P-gp. However, the function of chrysosplenetin on Bcrp/ABCG2 expression is still unknown, which is an obstacle for us to systematically evaluate the possibility of chrysosplenetin being as an inhibitor of artemisinin resistance.

Therefore, we here aimed to further investigate the impact of chrysosplenetin in the absence and presence of artemisinin on Bcrp/ABCG2 expression levels using by western blot and real time-quantitative polymerase chain reaction (RT-qPCR) methods.

Materials and methods

Artemisinin (white crystal) was purchased from Chongqing Huali Konggu Co., Ltd. (purity ≥99.0%, Chongqing, China). CHR (purity ≥98.0%) was purified in our lab from an acetone layer of artemisinin industrial waste materials using multiple column chromatography methods as described in the literature (Wei et al., 2015). The industrial wastes were kindly provided by Chongqing Huali Konggu Co., Ltd. and the voucher specimen (20100102) has been deposited with College of Pharmacy, Ningxia Medical University, for further references. Novobiocin was purchased from Hefei Bomei Biotechnology Co., Ltd. (CAS: 1476-53-5, purity ≥90%, China).

Healthy male ICR mice, weighing 18–22 g, were purchased from an animal centre of Ningxia Medical University (Ningxia, China). All animals were housed in polycarbonate cages and acclimated in an environmentally controlled room (23 ± 2 °C, with adequate ventilation and a 12-h light/dark cycle) prior to use and were provided with standard laboratory food and water before and during the experiments. The experimental protocol was approved by the University Ethics Committee (Ningxia Medical University, China; ethic approval: 2014-029). All procedures involving animals were in accordance with the Regulations of the Experimental Animal Administration, State Committee of Science and Technology. Animals were randomly divided into nine groups ($n = 6$ for each group) including negative control (0.5% sodium carboxymethylcellulose, CMC-Na), artemisinin alone (40 mg/kg), novobiocin (positive control, 100 mg/kg), novobiocin–artemisinin (positive control in combination, 1:1, 100:100 mg/kg), artemisinin–chrysosplenetin (1:0.1, 40:4 mg/kg), artemisinin–chrysosplenetin (1:1, 40:40 mg/kg), artemisinin–chrysosplenetin (1:2, 40:80 mg/kg), artemisinin–chrysosplenetin (1:4, 40:160 mg/kg), and chrysosplenetin alone (80 mg/kg). The drugs were intragastrically administrated once per day for consecutive seven days. Then the mice were euthanized and sacrificed by cervical vertebra dislocation. Small intestines were harvested and cleaned using normal saline at least three times. Total RNA was extracted from the mouse small intestine using E.Z.N.A.™ Total RNA Kit (OMEGA bio-tek, Norcross, GA, USA), in accordance with the manufacturer's instructions. RNA concentrations were measured with a microplate spectrophotometer (Bio-RAD, USA) at a wavelength of 260 nm. RNA quality was evaluated using electrophoresis in 1% agarose gels. Total RNA (3 μg) was reverse transcribed into first-strand complementary DNA (cDNA) using Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). Each cDNA sample (1 μl) was amplified with 12 μl of Thermo Scientific Maxima SYBR Green qPCR Master Mix (2X), ROX Solution (Thermo Scientific) and 1 μM of each primer. Amplification was performed in a RT-qPCR IQ5 System (Applied Biosystems, Foster City, USA) with the following parameters: denaturation at 94 °C for 2 min followed by 35 cycles of denaturation at 94 °C for 30 s, annealing at 61 °C for 30 s and extension at 72 °C for 45 s. The sequences of the oligonucleotide primers used for this study were 5′-GCA TTC GCT GTG GTT GAG T-3′ (sense) and 5′-TAT CCG TGG CAT CTC TGG A-3′ (antisense) for ABCG2 (product size, 123 bp from Sangon Biotech (Shanghai) Co., Ltd.); and 5′-GGT GAA GGT CGG TGT GAA CG-3′ (sense) and 5′-CTC GCT CCT GGA AGA TGG TG-3′ (antisense) for GAPDH (product size, 233 bp, from Invitrogen Biotechnology Co., Ltd.). The relative expression levels of ABCG2 in each sample (normalized to that of GAPDH) were determined using $2^{-\Delta\Delta Ct}$ method. All RT-qPCR experiments were repeated three times.

The total proteins were harvested by KenGEN Whole Cell Lysis Assay Kit (KenGEN BioTECH, Nanjing, China), and the protein concentrations were determined using KeyGEN BCA Protein Quantitation Assay kit (Nanjing KeyGEN Biotech, China). An equal quantity of protein (80 μg) from total protein was resolved using 7.5% SDS-PAGE gel and subsequently transferred onto nitrocellulose membranes (Bio-Trace). After blocking the membrane with 5% non-fat milk in Tris-buffered saline (Biotopped) at room temperature for 1 h, the membrane was incubated at 4 °C for 12 h with rabbit polyclonal antibody against ABCG2 (1:100; sc-25822, Santa Cruz) and mouse monoclonal antibody against β-actin (1:150; sc-47778, Santa Cruz). The membranes were incubated with horseradish Peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG and Goat Anti-Mouse IgG (ZSGB-BIO, Beijing, China) for 2 h and signals were observed using Super Signal West Pico (Thermo Scientific). Western blotting bands intensity was quantified by densitometric analysis using ImageJ version 2x (NIH Image software, Bethesda, MA, USA).

Data was analyzed using the SPSS 18.0 software (IBM, USA) and submitted to a one-way analysis of variance (ANOVA) to detect significant differences between study groups. Turkey's test was applied to identify any difference between means using a significance level of $p < 0.05$.

Results and discussion

Bcrp expression level in mice small intestine was measured by western blot assay. As displayed in Fig. 1, artemisinin alone down-regulated Bcrp level while chrysosplenetin alone up-regulated it when compared with negative control ($p < 0.05$). Novobiocin, a known specific Bcrp inhibitor (Duan and You, 2009) was observed to have no effect on Bcrp expression level versus vehicle. It is

Please cite this article in press as: Ma, W., et al. Impact of chrysosplenetin, per se or in combination with artemisinin, on breast cancer resistance protein (Bcrp)/ABCG2 mRNA expression levels in mice small intestine. Revista Brasileira de Farmacognosia (2017), https://doi.org/10.1016/j.bjp.2017.06.005